Fresenius Kabi has divested its Halden, Norway plant to the Prange Group, ensuring continued operations under a credible contract manufacturer.
Target Information
Fresenius Kabi has strategically decided to divest its manufacturing plant located in Halden, Norway, as part of its Vision 2026 initiative. This decision, announced in May 2023, was aimed at finding a buyer with a credible business plan that aligns with the company’s long-term goals. In November 2023, the Prange Group was selected as the buyer based on their established expertise in B2B contract development and manufacturing within the pharmaceutical sector.
The acquisition includes the plant, certain equipment, and the employment of all staff members. The financial specifics of the transaction were mutually agreed to remain confidential between the involved parties.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical industry in Norway is prominently known for its robust regulatory environment and high standards of quality. As a country with a strong focus on healthcare and biotechnology, Norway has
Similar Deals
PMG → Sørlandsparken Tverrfaglige Helse
2025
EG → PatientSky SaaS Norway AS and PatientSky APP AS
2023
Oris Dental → Tannlegene Eide & Steinsvoll AS
2022
Prange Group
invested in
Fresenius Kabi's plant in Halden
in 2023
in a Buyout deal